The supramolecular interaction of rubidate (chemically 2,3-naphthalenedicarboxylic acid, 1,4-dihydroxy-diethyl ester) and beta-cyclodextrin (beta-CD) has been studied by spectrofluorimetry. The influence of temperature on the supramolecular system has also been investigated and the thermodynamic parameters were calculated. The results show that beta-CD reacts with rubidate to form a 1:1 host-guest complex with an apparent association constant of 566+/-23 l mol(-1). It was also demonstrated that the thermodynamics of beta-CD-rubidate complex displayed a compensatory enthalpy-entropy relationship. Based on the significant enhancement of the fluorescence intensity of rubidate produced through complex formation, a spectrofluorimetric method for the determination of rubidate in bulk aqueous solution in the presence of beta-CD was developed. The linear relationship between the fluorescence intensity and rubidate concentration was obtained in the range from 2.7x10(-2) to 3.0 mug ml(-1), with a correlation coefficient of 0.9988. The detection limit was 8.2 ng ml(-1) and the relative standard deviation was 1.6%. There was no interference from the excipients normally used in tablet formulations. The application of the present method to the determination of rubidate in tablets gave satisfactory results and was compared with the reference method.

01 May 2001·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical and experimental study on effect of shuanghuang shengbai granule on myelosuppression induced by chemotherapy and ultrastructure observation of bone marrow in mice].

Article

Author: Zhu, Y W ; Zhou, W D ; Xu, Z Y

OBJECTIVETo observe the leukocyte increasing effects of Shaunghuang Shengbai Granule (SHSBG) in tumor patients treated by chemotherapy (CT) and its function on bone marrow hematopoietic microenvironment in mice.METHODSPatients of non-small-cell lung cancer and breast, gastric or intestinal cancer, who were retreated with CT, were enrolled and divided into 4 groups randomly. The 28 cases in the treated group 1 received SHSBG and CT simultaneously. The 27 cases in the treated group 2 also received firstly CT, and SHSBG started when WBC count lowered to less than 4 x 10(9)/L after CT. The control group 1 and 2 (n = 33 and n = 24) was treated by the method similar to that applied to the treated group 1 and 2 respectively but with Rubidate instead of SHSBG. Experimental study of observing bone marrow ultrastructure in mice was also conducted with electron microscopy.RESULTSThe total leukocyte increasing effective rate occurred in the treated group 1 was 75.00%, that in the treated group 2 was 88.89%, in the control group 1 was 54.55% and in the control group 2 was 58.33%. There was significant difference between the treated groups and the control groups (P < 0.01). Experimental study showed that SHSBG has good bone marrow hematopoietic microenvironmental protecting and improving effect in mice.CONCLUSIONSHSBG has obvious protecting and treating effect on CT caused bone marrow suppression in tumor patients.

01 Oct 1985·Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine

[The hematopoietic effects of rubidate and its toxicity].

Article

Author: Ding, L M ; Song, S Y

100 Deals associated with Rubidate

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Leukopenia	CN	Qidong Gaitianli Medicines Co., Ltd.	01 Jan 1990

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Rubidate

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation